

# CONTENTS

*Foreword*.....(v)  
*Preface*..... (vii)

## CHAPTER 1

### **GMP Regulations for Pharmaceutical Industry**

1.1 Basic Requirements of GMP ..... 1  
1.2 Organization Pillars in cGMP ..... 2  
    a. Management Responsibilities ..... 2  
    b. Resources..... 2  
    c. Manufacturing Operations ..... 2  
    d. Evaluation Activities ..... 2  
1.3 Six Quality System in GMP..... 3  
    A. Pharmaceutical Quality Management System..... 3  
    B. Production Management System..... 3  
        a. Technical Measures ..... 4  
        b. Organizational Measures..... 5  
    C. Facilities and Equipment Management System.....6  
    D. Laboratory Controls Management System.....6  
    E. Materials Management System.....7  
    F. Packaging and Labelling Management System.....7  
1.4 Quality Culture and Pharmaceutical Industry ..... 9

## CHAPTER 2

### **Good Laboratory Practices in Pharmaceutical Industry**

2.1 Good Laboratory Practice Equipment..... 11  
2.2 Documentation in Good Laboratory Practice ..... 12

2.3 Sampling in Good Laboratory Practice .....	12
A. Approaches for sampling plans will be discussed for .....	13
2.4 Testing in Good Laboratory Practice .....	13
2.5 Laboratory Reagents, Solutions, Reference Standards and Culture Media in Good Laboratory Practice .....	14
2.6 Glassware in Good Laboratory Practice .....	15
2.7 On-going stability programme in Good Laboratory Practice .....	15
2.8 Technical Transfer of Testing Methods in Good Laboratory Practice .....	16
2.9 Measures in Good Laboratory Practice .....	16

### CHAPTER 3

#### **Good Microbiology Practice in Pharmaceutical Industry**

3.1 Premises, Layout and Zone .....	18
3.2 Laboratory Environmental Monitoring .....	19
3.3 Laboratory Equipment .....	19
3.4 Personnel .....	20
3.5 Media and Preparation.....	20
A. Media procurement and Storage .....	20
B. Media Preparation .....	20
C. Media Incubation Time .....	21
3.6 Reference Culture.....	22
3.7 Sampling.....	22
3.8 Laboratory Testing.....	23
3.9 Disposal of Contaminated Waste.....	23
3.10 Laboratory Data Management .....	24

### CHAPTER 4

#### **Good Aseptic Practices in Pharmaceutical Industry**

4.1 The Industry's Approach to Validation of Aseptic Manufacturing .....	25
4.2 Cleanroom Classification .....	26
4.3 Environmental Monitoring.....	26

4.4 Methods of Microbiological Monitoring.....	26
4.5 Microbial Identification.....	26
4.6 Identification of Isolates .....	27
4.7 Essential Elements of the Environmental Control and Facility Management Program.....	27
4.8 Training for Aseptic Operations .....	28
4.9 Process Simulating Testing .....	28
4.10 Measure of Good Aseptic Practices .....	29

## CHAPTER 5

### **Good Clean Room Monitoring in Pharmaceutical Industry**

5.1 Content of ISO 14644-1:2015 .....	32
5.2 Sampling and Location Evaluations.....	32
5.3 Sampling .....	33
5.4 Sampling Procedure.....	33
5.5 Sampling Instruments: LSAPC - Light Scattering Airborne Particle Counter .....	33
5.6 Recording and Evaluations of Airborne Particle Concentration.....	34
5.7 ISO Class Number.....	34
5.8 Test Reports and Interpretation of Results.....	35
5.9 Out of Specifications .....	35

## CHAPTER 6

### **Good Engineering Practices in Pharmaceutical Industry**

6.1 Good Engineering Practice Overview .....	37
6.2 Key Concepts in Pharmaceutical Engineering.....	37
6.3 Using Good Maintenance Practice in Good Engineering.	38
6.4 Spares Management in Good Engineering Practice .....	39
6.5 Maintenance Qualification.....	40
6.6 Cost Cutting becomes the Pharma Industry's Mantra.....	40
6.7 Simplicity is the Ultimate Sophistication.....	41
6.8 Measures in Good Engineering Practices .....	42

**CHAPTER 7**

**Good Alarm Management Practices in  
Pharmaceutical Industry**

7.1 Key aspects of Alarm Management Program ..... 44

7.2 Regulators Expectation of Alarm Management System... 44

    A. FDA and Alarming ..... 44

    B. ISA-18.2 Alarm System Management Lifecycle ..... 45

7.3 Element of a Good Alarm on Risk Assessment in  
    Pharmaceutical Industry ..... 47

7.4 Categorization of Alarm ..... 47

7.5 Principle of Alarm Management System ..... 48

**CHAPTER 8**

**Good Computer Validation System Practices in  
Pharmaceutical Industry**

8.1 Computer Validation Master Plan..... 50

8.2 Computer Qualification ..... 50

    A. System Requirement Specifications (SRS) or User  
        Requirement Specifications (URS)..... 50

    B. Design Qualification and Specifications ..... 51

    C. Installation Qualification ..... 51

    D. Operational Qualification ..... 53

    E. Performance Qualification ..... 53

8.3 Validation Protocol/Report..... 54

8.4 Validation of Hardware and Software..... 55

**CHAPTER 9**

**Good Distribution Practices – Supply Chain Integrity  
in Pharmaceutical Industry**

9.1 Key components of Good Distribution Practice ..... 57

    A. Quality Management System ..... 57

    B. Supplier Qualification ..... 58

    C. Internal Audit ..... 58

    D. Storage Management System ..... 58

E. Environmental Condition Management .....	58
F. Temperature Mapping .....	59
G. Distribution Management System .....	60
9.2 Counterfeit .....	60
9.3 Supply Chain Integrity and Security .....	60
9.4 Category of Supply Chain Integrity and Security .....	61

## CHAPTER 10

### **Good Data Management System in Pharmaceutical Industry**

10.1 Regulatory Expectations .....	64
10.2 When does Electronic Data become a CGMP Record? .....	64
10.3 CIA or AIC Triangle.....	65
10.4 The Data Governance System.....	65
10.5 Designing Systems to Assure Data Quality and Integrity .....	66
10.6 Triggers of Data Integrity Loss.....	66
10.7 Data Integrity Metrics.....	67
10.8 Measures of Good Data Management System.....	67

## CHAPTER 11

### **Quality Agreements in Pharmaceutical Industry**

11.1 Elements of a Quality Agreement.....	68
11.2 Activities in Quality Agreements.....	69

## CHAPTER 12

### **Change control Management and its Applications**

12.1 Benefits of Change Control System .....	72
12.2 ICH Q8 and ICH Q9 to Change Management in ICH Q10 .....	73
12.3 Steps involved in Change Control Management.....	73
12.4 E-Change Control System.....	74

**CHAPTER 13**

**Technology Transfer of Pharmaceutical Product**

13.1 Different Types of Technology Transfer ..... 75  
13.2 Technology Transfer Protocol and Report..... 77

**CHAPTER 14**

**Pharmaceutical Annual Product Quality Review**

14.1 Importance of Annual Product Quality Review ..... 78  
14.2 Contents of APQR..... 79  
14.3 Data Trend and Analyzation ..... 80

**CHAPTER 15**

**Statistical Tools for Pharmaceutical Industry**

15.1 Concept of Six Sigma and Lean Manufacturing ..... 82  
15.2 Common Statistical Tools Pharmaceutical Industry can use to Meet Regulatory Requirements..... 83  
15.3 Other Statistical Tools used in Pharmaceutical Industry . 85  
15.4 Qualitative and Quantitative Analysis..... 88  
    A. Patterns and Trends..... 88  
15.5 Measures of Statistical Tools Analysis ..... 89

**CHAPTER 16**

**Application of Different Quality Tools in Investigation of Non-Conformance Observations**

16.1 Deviation Management ..... 90  
    A. Steps involved in Deviation Investigation ..... 91  
    B. Deviation Categorization ..... 91  
16.2 Complaint..... 92  
    A. Steps involved in Complaint Handling ..... 92  
16.3 Recall ..... 93  
    A. Classification of Recall..... 93  
    B. Recall Strategy ..... 93  
    C. Recall Communication ..... 94  
    D. Recall Status Reports ..... 95  
    E. Effectiveness Checks..... 95

16.4	Out of Specification (OOS).....	96
	A. Phase I: Laboratory Investigation .....	96
	B. Phase II: Full Scale Investigation .....	97
	a. Production Review .....	97
	b. Additional Laboratory Testing .....	98
16.5	Field Alter Report (FAR).....	99
16.6	Out of Trend (OOT) .....	100
16.7	Investigations Tools .....	100
	A. Root Cause Analysis (RCA).....	100
	B. Corrective and Preventive Action (CAPA) .....	101
	C. Risk Management Program.....	102
	a. Quality Risk Management Tools .....	103
16.8	Verification Program .....	105

## CHAPTER 17

### **New Approach to the Internal Audit from Traditional to Risk based Approach**

17.1	Traditional Approach to IA .....	107
17.2	Forecasting Approach to IA.....	107
17.3	Benefits of QRM to IA Program .....	108
17.4	IA Approach to Organization.....	109
	I. System based Approach.....	109
	A. Full Inspection Option .....	110
	B. Abbreviated Inspection Option .....	110
	II. Linked based -Process Approach .....	110
	III. Risk based approach for IA Program.....	111
	IV. Forensic Audit .....	111
	V. For-Cause-Audit.....	112
17.5	Planning.....	113
17.6	Audit Sampling .....	114
17.7	Audit Tools.....	115
17.8	Audit Evidence and Analysis Phase .....	116
17.9	Audit CLOSE-OUT and FOLLOW-UP .....	116

## CHAPTER 18

### Quality by Design (QbD) Approach in the Product Life Cycle

18.1 Elements of QbD .....	118
18.2 Steps involved in QbD Development Process.....	118
18.3 The Principle Steps in QbD are .....	119
18.4 QbD Documents .....	120
18.5 Process Analytical Technology (PAT) Frame Work.....	121
18.6 Use of PAT Tools in Continuous Manufacturing Process.....	121
A. PAT Tools .....	122
B. Risk-Based Approach .....	122
C. Integrated Systems Approach.....	122
D. Real Time Release .....	122
E. Strategy for Implementation .....	122
F. PAT Regulatory Approach .....	123
18.7 Product Life Cycle.....	123
A. Pharmaceutical Development .....	123
B. Technology Transfer.....	124
C. Commercial Manufacturing .....	124
D. Product Discontinuation .....	124
18.8 Definition.....	124

## CHAPTER 19

### Process Validation in Pharmaceutical Industry

19.1 Approach of Process Validation.....	127
A. Stage 1 - Process Design .....	127
B. Stage 2 - Process Qualification.....	128
C. Stage 3 - Continued Process Verification .....	129
D. Revalidation.....	129
19.2 Content of Validation Protocol/Report .....	129



**CHAPTER 20**

**Cleaning Validation and Cross Contamination  
Approach on Risk MaPP Concept**

20.1 Types of Cleaning ..... 131  
    A. Manual Cleaning ..... 132  
    B. Semi-Automated Processes Cleaning..... 132  
    C. Automated Processes Cleaning..... 132  
20.2 Approach for Cleaning Validation ..... 132  
20.3 Addition of New Product and Equipment to  
Validated Chain..... 133  
20.4 Equipment Hold Study Approaches ..... 133  
20.5 Selection of Worst Case Product ..... 133  
20.6 Cleaning Validation Protocol ..... 134  
    A. Indirect Sampling: Rinse Sampling ..... 134  
    B. Direct Sampling: Swab Sampling ..... 135  
20.7 Quality Risk based Approach for Cleaning Validation.. 136  
20.8 European Union Expectation on Cross Contamination . 137  
    A. EU chapter 5 expectation ..... 137  
    B. EMA ..... 138  
20.9 Selection & Reporting of the PDE  
Determination Strategy ..... 139  
20.10 Non-Penicillin Beta-Lactam Drugs:  
A CGMP Framework for Preventing  
Cross-Contamination ..... 139  
20.11 Definitions ..... 139

**CHAPTER 21**

**Pharmaceutical Water Generation and Distribution  
System and Regulatory Expectation**

21.1 Design and Process Flow ..... 143  
21.2 Steps involved in Pharmaceutical Water Preparations... 144  
21.3 Possible Pretreatment Method for Pharmaceutical  
Water Preparation..... 144

21.4 Possible Purification Method for Pharmaceutical Water Preparation .....	144
21.5 Qualification.....	145
A. User Requirement Specification (URS) .....	145
a. Process water .....	145
b. Purified water/ water for injection .....	145
c. Pure steam.....	145
B. Functional Design Specification (FDS).....	145
a. Process water .....	146
b. Purified water/WFI .....	146
c. Pure steam .....	146
C. Design Specification (DS).....	147
a. Process Water .....	147
b. Purified Water/WFI .....	147
c. Pure Steam .....	148
D. Performance Qualification for purified water / WFI/Pure Steam .....	148
a. Phase 1 :Test period : 2-4 weeks .....	148
b. Phase 2 : Test Period : 2-4 weeks .....	148
c. Phase 3: Test Period: 1 .....	148
E. Validation Cycle of Qualification and Validation of Water System .....	149
21.6 Component for Pharmaceutical Water System.....	150
A. Pretreatment System .....	150
a. Raw Water.....	150
b. Chlorination.....	150
c. Filtration .....	150
d. Dechlorination.....	150
e. Softener.....	150
f. Hardness .....	151
g. Oxidation Reduction Potential (ORP).....	151
h. Silt Density Indicator.....	151
i. Microbial-Retentive Filtration .....	151

B.	Purification System .....	152
a.	Ion Exchange .....	152
b.	Mixed bed demineralizers .....	152
c.	Reverse Osmosis .....	153
d.	Continuous Electro deionization (CEDI) or Electron De-ionization ( EDI) .....	153
C.	Storage and Distribution .....	153
a.	Storage Tanks .....	153
b.	Ultraviolet Light.....	154
c.	Distribution Systems .....	154
d.	Sanitization .....	155
e.	Total Organic Carbon (TOC).....	155
f.	Conductivity .....	155
g.	Flow of distribution loop .....	155
h.	Pressure .....	155
i.	Microfiltration .....	156
j.	Ultrafiltration.....	156
k.	PureSteam .....	156
21.7	Methods used for Preparation of Pharmaceutical Water .....	156
21.8	Test Performed for Potable Water and its Recommended Limits.....	157
21.9	Type of water is used in the Pharmaceutical Sterile Medicine Product as an Excipient as per EMA/CVMP/115/01 Note for Guidance on Quality of Water for Pharmaceutical Use .....	157
21.10	Type of water is used in the Pharmaceutical Non-Sterile Medicine Product as an Excipient as per EMA/CVMP/115/01 Note for Guidance on Quality of Water for Pharmaceutical Use.....	157

21.11	Type of Water is used in the Manufacturer of Active Pharmaceutical Ingredients (APIs) as per EMEA/CVMP/115/01 Note for Guidance on Quality of Water for Pharmaceutical Use .....	158
21.12	Type of Water is used for Cleaning/Rinsing of Equipment, Containers and Closure as per EMEA /CVMP/115/01 Note for Guidance on Quality of Water for Pharmaceutical Use.....	159
21.13	Potable Water as per Reference ISPE Baseline Guide, Volume- 4 Water and Steam System, WHO TRS 929 WHO TRS 937 .....	160
	A. Construction Requirement of Underground and Overage Storage Tank .....	160
	B. Control of Microbial load in Potable Water .....	161
	C. Dechlorination of Feed Water .....	161
	D. Procedure and limit of Hardness .....	161
	E. Procedure and limit of Oxidation Reduction Potential (ORP) .....	161
	F. Procedure and limit of Silt Density Indicator: .....	162
	G. Procedure for Microbial-Retentive Filters in Potable Water Line .....	162
	H. Potable Water Sampling and Testing .....	162
21.14	Purified Water and WFI System as per ISPE Baseline Guide, Volume 4 Water and Steam System, WHO TRS 929 WHO TRS 937 .....	162
	A. Design Requirement for Distribution of Purified Water and WFI System.....	162
	B. Storage Tank Design Requirement for Purified Water / WFI System .....	163
	C. Welding document Requirement during Design Qualification .....	163
	D. Flow velocity of Purified Water and WFI in Distribution Loop.....	163
	E. Conductivity Sensor .....	163

F. Pressure and Compound Gauge available in Purified Water and WFI System .....	163
G. Sampling procedure is for Purified and Water for Injection as per USP Chapter <1231> .....	163
H. Alert and Action levels defined for Purified and Water for Injection .....	164
I. Continuous System Monitoring of Purified Water and Water for Injection System .....	164
J. System Reviews of Purified Water and Water for Injection System .....	165
21.15 Planned Preventive Maintenance Programme .....	165
A. Potable/Purified/WFI/Pure Steam .....	165
B. Alarm Management for Purified/WFI/Pure Steam .....	165
C. RO Membrane Maintenance.....	165
D. Ion Exchange Membrane Maintenance.....	166
E. Continuous Electro deionization (CEDI) or Electron De-ionization (EDI) Maintenance .....	166
F. Total Organic Carbon (TOC).....	166
G. Sanitization for Purified and Water for Injection System .....	166
H. Ultra Violet lamp.....	167
I. Cleaning.....	167
21.16 Definition .....	167

## CHAPTER 22

### **Pharmaceutical Heating, Ventilation and Air Conditionings (HVAC) and Regulatory Expectations**

22.1 Qualification .....	170
A. Designed Qualification.....	170
I. Aseptic Dosage Form Facility .....	174
II. Check Points for Design Qualification for Aseptic and Biologics area .....	175
III. Design Criteria for Solid /Semi Solids/Liquids/ Final API.....	182

IV. Design Criteria for Potent Solid/Semi Solids/ Liquids/ Final API Form.....	183
V. Design Acceptance Criteria.....	186
VI. Check Points for Design Qualification Solid / Semi Solids/Liquids/ Final API (Potent and Non Potent).....	186
A. Installation Qualification.....	191
B. Operational Qualification .....	191
C. Performance Qualification.....	191
22.2 Regular Check Points of HVAC System .....	191
22.3 Definition.....	194

## CHAPTER 23

### **Manufacturing Execution System (MES) in Pharmaceutical Industry**

23.1 Overview of REPAC Model.....	198
23.2 Overview of Three-Layer-Model .....	199
23.3 Overview of Standards ISA S95.00.01/02/03 for MES ...	200
23.4 Systematic Planning Approach to MES Implementation in 14 Stages.....	201
23.5 MES Functions .....	202
23.6 Implementation Strategy.....	203

## CHAPTER 24

### **Pharmaceutical Drug Master File**

I. Submissions to Drug Master Files .....	205
II. Types of Drug Master File and its Contents.....	207
III. General Information and Suggestions.....	208
IV. Format, Assembly, and Delivery .....	208
V. Drug Master File submissions and correspondence should be addressed as follows.....	208
VI. Authorization to refer to a Drug Master File .....	208
VII. Processing and Reviewing Policies.....	209
VIII. Holder Obligations .....	209

IX. Major Reorganization of a Drug Master File.....	211
X. Closure of a Drug Master File .....	211
XI. Submission Process of Drug Product .....	211

## CHAPTER 25

### **Common Technical Document in Regulatory Filing**

25.1 Organization of the Common Technical Document .....	213
Module 1: Administrative Information and Prescribing Information .....	213
Module 2: Common Technical Document Summaries .....	213
Module 3: Quality .....	217
Module 4: Nonclinical Study Reports .....	220
Module 5: Clinical Study Reports .....	220
25.2 Electronic Common Technical Document .....	221

## CHAPTER 26

### **European Union Marketing Authorization**

A. Mutual Recognition Procedure (MRP).....	223
a. Steps involved in the mutual recognition procedure .....	223
b. Flow chart for the Mutual Recognition Procedure....	224
B. Decentralized Procedure.....	225
a. Steps involved in the Decentralised procedure .....	226
b. Flow Chart of the Decentralised Procedure .....	226
C. Numbering System for the Procedures for Mutual Recognition and Decentralised Procedure .....	228
D. Centralised authorisation procedure.....	229
a. Flow Chart of the Centralised Procedure .....	230

## CHAPTER 27

### **Site Master File**

27.1 Content of Site Master File.....	231
A. General Information on the Manufacturer .....	231

B. Quality Management system of the Manufacturer ...	232
C. Personnel.....	234
D. Premises and Equipment .....	234
E. Documentation.....	236
F. Production.....	236
G. Quality Control (QC).....	237
H. Distribution, Complaints, Product Defects and Recalls .....	237
I. Self-inspections.....	238
27.2 Appendix.....	238

## CHAPTER 28

### **Standard Operating Procedure (SOP)**

28.1 Writing Styles .....	240
28.2 SOP Process.....	240
28.3 SOP Review and Approval.....	241
28.4 Frequency of Revisions and Reviews.....	241
28.5 Checklists.....	241
28.6 Document Control.....	242
28.7 SOP Document Tracking and Archival.....	242
28.8 SOP General Format .....	243
28.9 Definitions.....	245

## CHAPTER 29

### **Quality Manual**

I. Contents of the Quality Manual.....	247
II. Topics that should be covered in the final section on Quality Policies for Specific Regulation Elements.....	249

## CHAPTER 30

### **Human Error Reduction: Pharma Industry Challenge**

30.1 How Do Industry and Regulatory Expectations and Approaches Differ? .....	253
--	-----



30.2 Understanding, Investigation & Tackling of Human Error.....	254
30.3 Power of 5-WHY .....	255
30.4 Human Error and Retraining .....	255
30.5 What Can Be Done for Human Error? .....	256
30.6 Measure of Human Error .....	257

## **CHAPTER 31**

### **Regulatory Inspections: Face Challenges through Proactive Measures**

31.1 Regulatory Expectations?.....	258
31.2 Current Regulatory Audits Looking .....	259
31.3 Regulators Looks at... ..	260
31.4 Audit Trail Assessments .....	261
31.5 An Approach to Managing Regulatory Risks and Achieving Compliance .....	262
31.6 Measures of Regulatory Inspections .....	263

## **CHAPTER 32**

### **Pharmaceutical GMP: Past, Present, and Future – A Review**

32.1 Current Expectations for Pharmaceutical Quality Systems.....	264
32.2 A Quality Culture That Leads to Sustainable Compliance .....	265
32.3 Quality Culture.....	265
32.4 Building Knowledge, Effective Monitoring & Control Systems.....	266
32.5 Global Supply Chain and Vendor Qualification .....	266
32.6 Bundling GMP Enforcement with Other Violations .....	267
32.7 Quality Systems .....	267
32.8 Change Control: New FDA Expectations for Equipment Changes.....	268
<i>References</i> .....	269